olaparib Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel. Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion Premium The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients. Uterine Leiomyosarcoma Sequences Point to Potentially Targetable Somatic Mutations Using genome, exome, or transcriptome sequences from dozens of uterine leiomyosarcoma samples, researchers found alterations that may respond to existing targetable treatments. Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs. FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer. Jul 31, 2020 Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications Jul 14, 2020 Genetic Alterations in Cyclin-Dependent Kinases Highlight Potential Cancer Treatment Approach May 20, 2020 FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer May 11, 2020 FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer Mar 30, 2020 Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic Feb 11, 2020 Myriad Files sPMA With FDA for Test to ID Best Responders to Lynparza, Avastin Combination Jan 21, 2020 Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer Dec 30, 2019 FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer Aug 7, 2019 Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study Aug 7, 2019 Myriad Genetics Seeking Additional FDA Approval for BRACAnalysis CDx Jul 1, 2019 FDA Approves Foundation Medicine CDx Test for Lynparza Jun 19, 2019 AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan Jun 6, 2019 TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts Premium Jun 3, 2019 Lynparza Delays Progression in Metastatic Pancreatic Cancer Patients With Germline BRCA Mutations Premium May 16, 2019 NCI Pediatric MATCH Trial Interim Data Shows 24 Percent of Patients Eligible for Targeted Therapy Premium Apr 4, 2019 Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration Apr 2, 2019 Treatment With Less Toxic Rubraca in Molecularly-Defined Pancreatic Cancer Subset Proposed at AACR Premium Dec 19, 2018 FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting Apr 2, 2018 Japanese Regulators Approve Myriad Genetics' BRACAnalysis Test Jan 12, 2018 FDA Approves Myriad CDx With AstraZeneca Drug for BRCA-Mutated Breast Cancer Patients Load More Breaking News Delic Partners With GT Research for Genetic Analysis of Cannabis, Psychedelic Mushrooms Indivumed, Biognosys Expand Partnership to Offer Immunopeptidomics Insights Multiomic Study Identifies Drivers of Severe COVID-19 in Patients Under 50 Without Comorbidities Yourgene H1 2022 Revenues More Than Double Gencove Raises $10M in Series A Financing Blueprint Genetics, BioMarin to Offer Genetic Testing for Skeletal Dysplasia in Europe, Middle East The Scan Should've Been Spotted Sooner Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier. For Martian Fuel Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo. To Boost Rapid Testing The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests. PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.